Journal profile · Endocrinology & Metabolism
Endocrine Related Cancer
ISSN 1351-0088 · eISSN 1479-6821 · BioScientifica Ltd. · ENGLAND · Quarterly · Founded 1994
Endocrine Related Cancer: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 4.29; hybrid open access; median 151 days to acceptance (107 articles, last 24 months); community-reported acceptance: moderate; 120 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Endocrine Related Cancer is published by BioScientifica Ltd. and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Neuroendocrine Tumor Research Advances, Thyroid Cancer Diagnosis and Treatment and Estrogen and related hormone effects, together about 28.9% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Endocrine Caner Journals are a cutting-edge journal dedicated to advancing knowledge and understanding in the field of endocrine cancer.With contributions from renowned experts and thought leaders, offers a platform for the latest research, clinical trials, and breakthroughs in the diagnosis, treatment, and management of endocrine-related tumors.
From the journal's Aims & Scope
Research area (LetPub): Endocrinology & Metabolism
Main research topics OpenAlex counts of recent articles; shares are approximate
- Neuroendocrine Tumor Research AdvancesMedicine10.7%
- Thyroid Cancer Diagnosis and TreatmentMedicine9.4%
- Estrogen and related hormone effectsBiochemistry, Genetics and Molecular Biology8.8%
- Adrenal and Paraganglionic TumorsMedicine6.8%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology6.6%
- Neuroblastoma Research and TreatmentsMedicine6.4%
- Pituitary Gland Disorders and TreatmentsMedicine5.8%
- Prostate Cancer Treatment and ResearchMedicine5.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Endocrinology & Metabolism | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Endocrinology & Metabolism | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.29LetPub ·
- CiteScore 2026-06
- 7.2LetPub ·
- SJR 2026-06
- 1.54LetPub ·
- SNIP 2026-06
- 1.41LetPub ·
- h-index
- 119LetPub ·
- h-index
- 173OpenAlex ·
- i10-index
- 2,154OpenAlex ·
- 2-year mean citedness
- 2.71OpenAlex ·
- Self-citation rate
- 4.5%LetPub ·
- Share of gold OA articles
- 23.78%LetPub ·
Volume
- Articles per year
- 121LetPub ·
Articles by year OpenAlex count · 2,900 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 113 | 56 | 37 |
| 2025 | 120 | 50 | 327 |
| 2024 | 73 | 31 | 464 |
| 2023 | 104 | 77 | 1,306 |
| 2022 | 75 | 37 | 1,367 |
| 2021 | 104 | 70 | 2,608 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
151 daysMedian, submission to acceptance · P25–P75 100 days – 203 days
- Acceptance to online
- median 19 days (63 articles)
- Submission to online
- median 172 days
- Sample
- 107 articles with submission and acceptance dates (262 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websitePeer review
- Peer review
Peer review is mentioned; articles are peer reviewed. Model summary
To read the latest articles pier reviewed articles on endorcrinology please login.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BioScientifica Ltd.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Quarterly
- Founded
- 1994
- ISSN
- 1351-0088
- Electronic ISSN
- 1479-6821
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Endocrine Related Cancer
What CAS zone is Endocrine Related Cancer in?
In the 2025 upgraded edition of the CAS Journal Ranking, Endocrine Related Cancer is in Zone 2 of Medicine, and in Zone 2 of the minor category Endocrinology & Metabolism / Oncology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Endocrine Related Cancer?
The latest impact factor listed by LetPub is 4.29; CiteScore 7.2, h-index 173.
How long does peer review take at Endocrine Related Cancer?
Based on the dates recorded on 107 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 151 days (interquartile range 100–203 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Moderate”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Endocrine Related Cancer?
According to LetPub and DOAJ records, Endocrine Related Cancer is indexed in SCIE and Scopus.
Is Endocrine Related Cancer open access, and what is the APC?
Endocrine Related Cancer is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .